Valproate induced encephalopathy treated with carnitine in an adult

Hepatotoxicity due to valproate often necessitates discontinuation of the drug. We report a patient with unstable epilepsy in whom valproate was an irreplaceable component of anticonvulsant treatment. Hepatic encephalopathy was reversed and remittance controlled by combining carnitine supplementation with an essentially unchanged valproate schedule.

A 35 year old previously healthy woman developed status epilepticus as a result of viral encephalitis initially requiring mechanical ventilation and phenobarbitone concentrations of over 100 mg/l with phenytoin to maintain seizure control. Phenytoin was discontinued due to rash and replaced by carbamazepine, which was subsequently withdrawn due to abnormal liver function tests and sedation. Valproate was initiated in combination with phenobarbitone. Isolated generalised breakthrough seizures sometimes associated with urinary tract infections continued during a period of rehabilitation.

Thirteen months after her initial illness, she was again admitted after three days of increasing confusion, drowsiness, and tremulousness without seizure activity. On examination, delirium with asterixis raised the clinical suspicion of hepatic encephalopathy. Liver function tests showing white blood count and liver function tests were normal, and anticonvulsant concentrations were therapeutic (phenobarbitone 34-2 mg/l, valproate 83 mg/l). Serum ammonia on admission was 43 mmol/l (normal <33 mmol/l), rising to 215 mmol/l by the next morning. Serum free carnitine was 7-6 mmol/l (normal 19-0-60-0 mmol/l) and total carnitine 15-4 mmol/l (normal 30-0-73-0 mmol/l). Phenobarbitone was maintained and valproate decreased from 3 g to 2-75 g a day with supplemental L-carnitine added (330 mg four times daily). The delirium and asterixis resolved over the next three days permitting discharge on the fourth hospital day with normal serum ammonia (25 mmol/l) and therapeutic valproate concentration (93 mmol/l).

Valproate has been shown to cause reduced serum carnitine concentrations and hyperammonaemia in certain children when compared with the administration of other anticonvulsant drugs. However, not all patients receiving valproate induced hepatotoxicity is carnitine related. Children at greatest risk are those receiving a multidrug anticonvulsant regimen. The condition usually develops within a few months of starting valproate.

Carnitine supplementation has been used to prevent hepatotoxicity in certain conditions but most experience considered at increased risk due to suspected mitochon- dridial disorder, malnutrition, mental retardation, high dose valproate treatment, or a history of hepatotoxicity to the valpo rate.1 Treatment with carnitine has also been reported to reverse this hepatotoxicity in children despite continued valproate.2

Less is known about the relation between valproate induced hepatotoxicity and carnitine deficiency in adults. Reduced free carnitine concentrations have been reported in 76-5% of adults receiving anticonvulsant drug regimens including valproate compared with 21-5% of adults on schedules without valproate.3 Coma from valproate induced carnitine deficiency in adults is reported to respond rapidly to discontinuation of the drug.4

This case shows that certain adults receiving valproate are, like children, at risk for carnitine deficiency and hyperammonaemia with its clinical accompaniment. The incidence among encephalititis in children on valproate is unknown. This patient further illustrates that identification and correction of a drug induced deficiency may allow continuation of treatment without disturbing control of an unstable seizure disorder. Much as folate is used in chronic phenytoin administration, supplemental carnitine should be considered in adult patients with epilepsy at risk for hyperammonaemia.

DAVID BEVERS DORF
COLIN ALLEN
Department of Neurology
University of Florida College of Medicine
Gainesville, FL 32610, USA

Increased serum neopterin concentrations in a patient with Creutzfeldt-Jakob disease

Spongiform encephalopathies or prion diseases affect both human beings and animals. The human transmissible spongiform encephalopathies include Kuru, Creutzfeldt- Jakob disease, and the Gerstmann- Straussler-Scheinker syndrome (GSS), and familial cerebellar ataxias; all these diseases are associated with the accumulation of β-pleated amyloid protein in the brain.1 Besides genetic abnormalities, epidemiological studies disclosed that a transmissible agent is involved in the spread of Creutzfeldt-Jakob disease, and small virus-like structures were identified in human and familial Creutzfeldt-Jakob disease and GSS have been described.2 More recently the possible association between bovine spongiform encephalopathies and Creutzfeldt- Jakob disease received renewed interest.3

In a study comprising patients with neurodegenerative disorders we had the opportunity to examine a 67 year old woman who suffered from a chronic and probably viral Creutzfeldt-Jakob disease. She had shown rapidly progressive dementia, typical EEG patterns, and myoclonus; intercurrent illness was apparent. The woman died five months after the onset of clinical symptoms and was found in necropsy, performed by one of us (JK), diffuse spongiform changes were found in the cerebral cortex, thalamus, striatum, and cerebellum associated with neuronal loss and neuronal and astroglial hypertrophy, confirming the diagnosis of Creutzfeldt-Jakob disease. Blood specimens were obtained two months and one month before death. Among other routine laboratory tests, neopterin concentrations in serum were measured by enzyme-linked immunoassay (ELISA; BRAHMS- Diagnostica, Berlin, Germany). Neopterin concentrations were 16-3 nmol/l (first occasion) and 12-4 nmol/l (second occasion), clearly raised compared with the serum neopterin concentrations in healthy controls (mean SD) 3-4 (2-3) nmol/l.1

Increased neopterin concentrations are indicative of activation of cell mediated immunity in humans, because large amounts of neopterin are released from human monocytes and macrophages on stimulation with interferon-γ.5 Similarly, increased serum concentrations of neopterin have been reported in body fluids of patients with infections, autoimmune disorders, or certain types of malignancies, usually correlating with the extent and the activity of the diseases and giving prognostic information.6 Also in various infections of the CNS increased neopterin concentrations, preferentially in the CSF, have been reported.7 Thus increased serum and CSF neopterin concentrations were measured in our patient and in one control individual with Creutzfeldt-Jakob disease but provides a hint that the cell mediated immune system was chronically activated in our patient with late stage Creutzfeldt-Jakob disease. This is surprising in view of the lack of evidence so far that prion diseases are associated with abnormal cellular immunity. We are unable to deduce at which stage of disease immune deterioration may start in Creutzfeldt-Jakob disease, when an increase of serum neopterin may begin, and whether the presence of any transmissible agent was the cause of increased neopterin in the present patient. Further studies involving further number of patients are required to answer these questions.

F LEBLHUBER
WALLI
Department of Gerontology,
Landesversenklinik Wagenfeld, Linz, Austria

G TILZ
Department of Internal Medicine, University of Graz, Graz, Austria

F JELLINGER
Department of Neurology and Ludwig Boltzmann Institute of Neurobiology, Linz-Hospital, Vien, Austria

H WACHTER
Institute of Medical Chemistry and Biochemistry and Ludwig Boltzmann Institute of AIDS-Research, University of Innsbruck, Innsbruck, Austria
Correspondence to: Dr D Fuchs, Institute of Medical Chemistry and Biochemistry, University of Innsbruck, Fritz Pregl Strasse 3, A-6020 Innsbruck, Austria.


Increased serum neopterin concentrations in a patient with Creutzfeldt-Jakob disease.

F Leblhuber, J Walli, G P Tilz, K Jellinger, H Wachter and D Fuchs

*J Neurol Neurosurg Psychiatry* 1996 61: 211-212
doi: 10.1136/jnnp.61.2.211-a

Updated information and services can be found at:
http://jnnp.bmj.com/content/61/2/211.2.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/